Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Deal Watch

Brexit: the facts (and the alternative facts)

How Brexit affects pharma

- PMLiVE

Brexit: Implications for the pharma industry

From patents to the EMA, data protection to clinical trials, there's a lot that should be a concern

Can UK pharma rise to the post-Brexit challenge?

Our dominant and thriving industry is one we should be proud of

- PMLiVE

Boehringer Ingelheim calls for “strong and united” Europe

Simone Menne highlights the EU's achievements, and her firm's contribution

- PMLiVE

Connecting the dots

What happens ‘here’ impacts what happens ‘there’

- PMLiVE

UK pharma strikes optimistic note as Brexit process begins

Says life science industry is accustomed to ‘uncertainty’ and can thrive in a post-EU Britain

- PMLiVE

Brexit begins as UK PM signs letter triggering Article 50

Theresa May sets wheels in motion as Britain awaits EU response

UK flag

ABPI delivers wish-list to Hammond ahead of spring budget

Pharma industry has three key requests

- PMLiVE

Bayer: Post-truth politics severely handicaps innovation

And firm also voices its concerns over Brexit

- PMLiVE

2016: The year when deal-makers took stock?

Merger-mania and asset swaps slowed and joint ventures were back in fashion

- PMLiVE

Innovation and the pharma patent court

As the UK prepares to exit the European Union a unified patent system is still essential

- PMLiVE

Denmark pitches for EMA, with help from ex Novo Nordisk CEO

Lars Rebien Sørensen to serve as special envoy to promote Danish candidacy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links